Claims for Patent: 9,101,622

Summary for Patent: 9,101,622

Title:	Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone
Abstract:	Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Inventor(s):	Zeldis; Jerome B. (Princeton, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	14/482,745
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,101,622
Patent Claims:	1. A method of treating multiple myeloma, which comprises administering in a 28 day cycle to a patient having multiple myeloma: (a) about 1 to about 50 mg per day of a compound having the formula: ##STR00009## or a pharmaceutically acceptable salt, solvate or stereoisomer thereof for 21 consecutive days followed by seven consecutive days of rest from administration of said compound, and (b) a therapeutically effective amount of dexamethasone during such 28 day cycle, wherein the patient has not received previous treatment for multiple myeloma. 2. The method of claim 1, wherein the compound is ##STR00010## and is not a pharmaceutically acceptable salt, solvate or stereoisomer thereof. 3. The method of claim 1, wherein the compound is a pharmaceutically acceptable salt. 4. The method of claim 1, wherein the compound is a pharmaceutically acceptable solvate. 5. The method of claim 1, wherein the compound is a pharmaceutically acceptable stereoisomer. 6. The method of claim 1, wherein the patient is ineligible for stem cell transplantation. 7. The method of claim 1, wherein the patient is 65 years of age or older. 8. The method of claim 1, wherein the patient is younger than 65 years of age. 9. The method of claim 6, wherein the patient is younger than 65 years of age. 10. The method of claim 1, wherein the compound is administered in an amount of about 25 mg per day. 11. The method of claim 1, wherein the compound is administered in an amount of about 20 mg per day. 12. The method of claim 1, wherein the compound is administered in an amount of about 15 mg per day. 13. The method of claim 1, wherein the compound is administered in an amount of about 10 mg per day. 14. The method of claim 1, wherein the compound is administered in an amount of about 5 mg per day. 15. The method of claim 1, wherein the compound is administered in an amount of about 2.5 mg per day. 16. The method of claim 1, wherein the compound is administered orally. 17. The method of claim 16, wherein the compound is administered in the form of a capsule or tablet. 18. The method of claim 17, wherein the compound is administered in a capsule in an amount from about 1 mg to about 50 mg. 19. The method of claim 18, wherein the compound is administered in a capsule in an amount of about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg or about 25 mg. 20. The method of claim 17, wherein the capsule comprises the compound, lactose anhydrous, microcrystalline cellulose, croscarmellose sodium and magnesium stearate. 21. The method of claim 1, wherein the dexamethasone is administered in an amount of 40 mg per day on days 1-4 of each 28 day cycle. 22. The method of claim 1, wherein the dexamethasone is administered in an amount of 40 mg per day on days 1, 8, 15 and 22 of each 28 day cycle. 23. The method of claim 1, which further comprises administering a therapeutically effective amount of an additional active agent. 24. The method of claim 23, wherein the additional active agent is melphalan, doxorubicin, vincristine, prednisone, cyclophosphamide, biaxin, a proteasome inhibitor, or a combination thereof. 25. The method of claim 1, wherein the solvate is hydrate.